Reslizumab

Name: Reslizumab - Evidentic GmbH
Price: 187.00 EUR
Availability: InStock

BATCH NUMBER: To be announced

187,00 €

Minimum order quantity: 11

Therapeutic Reslizumab antibody from the original Cinqaero® commercial drug

Drug Aliquots On Demand

*Subject to availability and market fluctuations.

Product specifications:

Product Concentration 10 mg/mL
Volume per vial 100 µL
Quantity per vial 1 mg
Batch Number to be announced
Storage Temperature 2-8 °C / -80 °C

Expiry Date: to be announced

Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient adminstration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

Procurement of original drug products (RMP).

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.

Production of drug aliquots from RMP

Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.

Labeling of drug aliquots

For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.

Storage of drug aliquots

Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.

Target

IL-5

Class of molecule

Monoclonal Antibody

Isotype

IgG4 kappa- Humanized

Host cells

Mouse myeloma cells

Prepared from

Cinqaero®

Therapeutic Area

Obstructive airway diseases

Therapeutic Indications

Eosinophilic asthma

Mechanism of Action (MoA)

Reslizumab is a humanised monoclonal antibody (IgG4, κ) against the human interleukin-5 (IL-5).Reslizumab binds specifically to IL-5 and interferes with IL-5 binding to its cell-surface receptor. IL-5is a key cytokine responsible for the differentiation, maturation, recruitment and activation of humaneosinophils. Reslizumab binds human IL-5 with picomolar affinity blocking its biological function;consequently survival and activity of eosinophils are reduced.

Pharmacotherapeutic group

Drugs for obstructive airway diseases, other systemic drugs forobstructive airway diseases

List of Excipients

Sodium acetate trihydrate
Acetic acid glacial
Sucrose
Water for injections

Not looking for Reslizumab?

Search our therapeutic molecules product database